Abstract: A touch controller is coupled to a touch screen and detects a first gesture at a first point on the touch screen. The first gesture includes physical contact of the touch screen by a user device at the first point. The touch controller detects a second gesture that is associated with movement of the user device from the first point to a second point on the touch screen. The second gesture includes detecting movement of the user device within a sensing range from the first point to the second point. The sensing range corresponds to an orthogonal distance from a surface of the touch screen. The touch controller detects a third gesture at the second touch point. The third gesture includes physical contact of the touch screen at the second touch point. Upon detecting the first, second and third gestures the touch controller performs a corresponding action.

Abstract: A method of pairing an intelligent input device with an electronic device includes transmitting a start pairing identifier and receiving a unique identifier that identifies the intelligent input device. The method further includes authenticating the unique identifier using authentication information stored in the electronic device and transmitting a pairing successful identifier responsive to the unique identifier being authenticated to thereby pair the intelligent input device and the electronic device.

Abstract: A touch controller is coupled to a touch screen and detects a first gesture at a first point on the touch screen. The first gesture includes physical contact of the touch screen by a user device at the first point. The touch controller detects a second gesture that is associated with movement of the user device from the first point to a second point on the touch screen. The second gesture includes detecting movement of the user device within a sensing range from the first point to the second point. The sensing range corresponds to an orthogonal distance from a surface of the touch screen. The touch controller detects a third gesture at the second touch point. The third gesture includes physical contact of the touch screen at the second touch point. Upon detecting the first, second and third gestures the touch controller performs a corresponding action.

Abstract: A method comprises during a frame period finding a first EFT noise influenced sensor of a touch screen panel, determining whether the first EFT noise influenced sensor is located at a last transmitting/driving line of the touch screen panel, designating the frame period as a noise influenced frame period using an absolute value threshold if the first EFT noise influenced sensor is not located at the last transmitting/driving line and designating the frame period as the noise influenced frame period using a percentage threshold if the first EFT noise influenced sensor is located at the last transmitting/driving line.

Abstract: A display screen is configured to display information with a selectable one of many information display orientations. A touch screen panel of a touch screen system is positioned to overlie the display screen. The touch screen system operates to make a proximate touch detection, for example by a body part or stylus. A controller receives the proximate touch information from the capacitive touch screen system and interprets the proximate touch information to determine an indication from a user of a selection of an information display orientation for the display screen. The controller then controls the display screen to present information in accordance with the user selected information display orientation. The user selected information display orientation via the proximate touch detection will over-ride any other selected information display orientation such as a selection made in response to an orientation identified by an accelerometer or other gravity influenced sensor.

Abstract: A method of generating a chronic myelogenic leukemia (CML) acquired chemoresistant culture model is provided. Such a method may comprise providing a naïve blast crisis CML cell line; administering/contacting the cell line with a mutation-inducing dose of imatinib; maintaining a culture of the treated cell line for a period of time until the treated cell line relapses and repopulates the culture; and determining the repopulated cell culture is a CML acquired chemoresistant cell line by detecting a BCR-ABL mutation, wherein the acquired chemoresistance is achieved by a BCR-ABL mutation.

Abstract: A method of generating a chronic myelogenic leukemia (CML) acquired chemoresistant culture model is provided. Such a method may comprise providing a naïve blast crisis CML cell line; administering/contacting the cell line with a mutation-inducing dose of imatinib; maintaining a culture of the treated cell line for a period of time until the treated cell line relapses and repopulates the culture; and determining the repopulated cell culture is a CML acquired chemoresistant cell line by detecting a BCR-ABL mutation, wherein the acquired chemoresistance is achieved by a BCR-ABL mutation.

Abstract: In one embodiment, a gene expression signature for predicting risk of developing therapy-related myelodysplasia or acute myeloid leukemia (t-MDS/AML) after autologous hematopoietic cell transplantation (aHCT) is provided. In another embodiment, a method for predicting a risk for development of t-MDS/AML after aHCT is provided. Such a method may include providing a biological sample that contains CD34 cells from a subject; detecting a test expression level of a set of two or more genes of a gene expression signature; comparing the test expression level of a set of corresponding training expression levels that include a training case expression level and a training control expression level; and predicting a high risk of developing t-MDS/AML when the test expression level is at or about the training case expression level or predicting a low risk of developing t-MDS/AML when the test expression level is at or about the training control expression level.

Abstract: A method of generating a chronic myelogenic leukemia (CML) acquired chemoresistant culture model is provided. Such a method may comprise providing a naïve blast crisis CML cell line; administering/contacting the cell line with a mutation-inducing dose of imatinib; maintaining a culture of the treated cell line for a period of time until the treated cell line relapses and repopulates the culture; and determining the repopulated cell culture is a CML acquired chemoresistant cell line by detecting a BCR-ABL mutation, wherein the acquired chemoresistance is achieved by a BCR-ABL mutation.